PC-C7

Sprague-Dawley (male and female, 220-250 g)^[1]

10 mg/kg (oral gavage); 20 mg/kg (oral gavage); 1 μg/μL, 20 μL (intra-articular injection)

oral gavage; intra-articular injection; once daily; 10 consecutive days

Reduced joint swelling and promoted recovery of joint thickness over the observation period, with overall efficacy comparable to Dex (Figure 8A,B; img-p10-b6-1).
Alleviated ACLT-induced joint tissue damage, with improved tissue architecture and reduced inflammatory lesions (Figure 8C; img-p10-b8-1).
Significantly reduced elevated IL-1β, IL-6, and TNF-α levels in synovial tissues of ACLT-induced OA rats (Figure 8D-F).
Micro-CT showed partially preserved joint bone structure and significantly restored BV/TV and BMD in diseased animals (Figure 9A-C; img-p11-b4-1).
In synovial tissues, reduced TLR4, MD2, MyD88, and TRAF6 protein levels and decreased the p-p65/p65 ratio after both systemic and intra-articular administration, with the 20 mg/kg dose producing stronger inhibition than 10 mg/kg (Figure 10A-F).
Immunofluorescence showed that increased p-NF-κB p65 and MyD88 signals in model rat synovial tissues were reduced (Figure 11; img-p12-b3-1).
Reduced MMP3 and MMP13 fluorescence signals in rat joint tissues, with more pronounced effects in the 20 mg/kg and intra-articular injection groups (Figure S3A,B).